Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 289

1.

SUMOylation and ubiquitination reciprocally regulate α-synuclein degradation and pathological aggregation.

Rott R, Szargel R, Shani V, Hamza H, Savyon M, Abd Elghani F, Bandopadhyay R, Engelender S.

Proc Natl Acad Sci U S A. 2017 Dec 12;114(50):13176-13181. doi: 10.1073/pnas.1704351114. Epub 2017 Nov 27.

2.

Glycation potentiates α-synuclein-associated neurodegeneration in synucleinopathies.

Vicente Miranda H, Szego ÉM, Oliveira LMA, Breda C, Darendelioglu E, de Oliveira RM, Ferreira DG, Gomes MA, Rott R, Oliveira M, Munari F, Enguita FJ, Simões T, Rodrigues EF, Heinrich M, Martins IC, Zamolo I, Riess O, Cordeiro C, Ponces-Freire A, Lashuel HA, Santos NC, Lopes LV, Xiang W, Jovin TM, Penque D, Engelender S, Zweckstetter M, Klucken J, Giorgini F, Quintas A, Outeiro TF.

Brain. 2017 May 1;140(5):1399-1419. doi: 10.1093/brain/awx056.

PMID:
28398476
3.

The PINK1, synphilin-1 and SIAH-1 complex constitutes a novel mitophagy pathway.

Szargel R, Shani V, Abd Elghani F, Mekies LN, Liani E, Rott R, Engelender S.

Hum Mol Genet. 2016 Aug 15;25(16):3476-3490. doi: 10.1093/hmg/ddw189. Epub 2016 Jun 22.

PMID:
27334109
4.

Site-specific differences in proteasome-dependent degradation of monoubiquitinated α-synuclein.

Abeywardana T, Lin YH, Rott R, Engelender S, Pratt MR.

Chem Biol. 2013 Oct 24;20(10):1207-13. doi: 10.1016/j.chembiol.2013.09.009.

5.

α-Synuclein ubiquitination and novel therapeutic targets for Parkinson's disease.

Rott R, Szargel R, Shani V, Bisharat S, Engelender S.

CNS Neurol Disord Drug Targets. 2014;13(4):630-7. Review.

PMID:
24168368
6.

AF-6 is a positive modulator of the PINK1/parkin pathway and is deficient in Parkinson's disease.

Haskin J, Szargel R, Shani V, Mekies LN, Rott R, Lim GG, Lim KL, Bandopadhyay R, Wolosker H, Engelender S.

Hum Mol Genet. 2013 May 15;22(10):2083-96. doi: 10.1093/hmg/ddt058. Epub 2013 Feb 7.

7.

α-Synuclein fate is determined by USP9X-regulated monoubiquitination.

Rott R, Szargel R, Haskin J, Bandopadhyay R, Lees AJ, Shani V, Engelender S.

Proc Natl Acad Sci U S A. 2011 Nov 15;108(46):18666-71. doi: 10.1073/pnas.1105725108. Epub 2011 Nov 7.

8.

Periphilin is a novel interactor of synphilin-1, a protein implicated in Parkinson's disease.

Soehn AS, Franck T, Biskup S, Giaime E, Melle C, Rott R, Cebo D, Kalbacher H, Ott E, Pahnke J, Meitinger T, Krüger R, Gasser T, Berg D, von Eggeling F, Engelender S, da Costa CA, Riess O.

Neurogenetics. 2010 May;11(2):203-15. doi: 10.1007/s10048-009-0215-z.

PMID:
19730898
9.

Synphilin-1A inhibits seven in absentia homolog (SIAH) and modulates alpha-synuclein monoubiquitylation and inclusion formation.

Szargel R, Rott R, Eyal A, Haskin J, Shani V, Balan L, Wolosker H, Engelender S.

J Biol Chem. 2009 Apr 24;284(17):11706-16. doi: 10.1074/jbc.M805990200. Epub 2009 Feb 17.

10.

Monoubiquitylation of alpha-synuclein by seven in absentia homolog (SIAH) promotes its aggregation in dopaminergic cells.

Rott R, Szargel R, Haskin J, Shani V, Shainskaya A, Manov I, Liani E, Avraham E, Engelender S.

J Biol Chem. 2008 Feb 8;283(6):3316-28. Epub 2007 Dec 10.

11.

Synphilin-1 isoforms in Parkinson's disease: regulation by phosphorylation and ubiquitylation.

Szargel R, Rott R, Engelender S.

Cell Mol Life Sci. 2008 Jan;65(1):80-8. Review.

PMID:
17982729
12.

Phosphorylation of Parkin by the cyclin-dependent kinase 5 at the linker region modulates its ubiquitin-ligase activity and aggregation.

Avraham E, Rott R, Liani E, Szargel R, Engelender S.

J Biol Chem. 2007 Apr 27;282(17):12842-50. Epub 2007 Feb 27.

13.

Synphilin-1A: an aggregation-prone isoform of synphilin-1 that causes neuronal death and is present in aggregates from alpha-synucleinopathy patients.

Eyal A, Szargel R, Avraham E, Liani E, Haskin J, Rott R, Engelender S.

Proc Natl Acad Sci U S A. 2006 Apr 11;103(15):5917-22. Epub 2006 Apr 4.

14.
15.

Ubiquitylation of synphilin-1 and alpha-synuclein by SIAH and its presence in cellular inclusions and Lewy bodies imply a role in Parkinson's disease.

Liani E, Eyal A, Avraham E, Shemer R, Szargel R, Berg D, Bornemann A, Riess O, Ross CA, Rott R, Engelender S.

Proc Natl Acad Sci U S A. 2004 Apr 13;101(15):5500-5. Epub 2004 Apr 2.

16.

RNA polyadenylation and degradation in cyanobacteria are similar to the chloroplast but different from Escherichia coli.

Rott R, Zipor G, Portnoy V, Liveanu V, Schuster G.

J Biol Chem. 2003 May 2;278(18):15771-7. Epub 2003 Feb 21.

18.

Borna disease virus: a mystery as an emerging zoonotic pathogen.

Richt JA, Rott R.

Vet J. 2001 Jan;161(1):24-40. Review.

PMID:
11145828
19.

[Werner Schäfer. A life as researcher and teacher].

Rott R, Thiel HJ, Moennig V.

Dtsch Tierarztl Wochenschr. 2000 Jul;107(7):282-7. German.

PMID:
10955000
20.

Altering the 3 UTR endonucleolytic cleavage site of a Chlamydomonas chloroplast mRNA affects 3-end maturation in vitro but not in vivo.

Rott R, Liveanu V, Drager RG, Higgs D, Stern DB, Schuster G.

Plant Mol Biol. 1999 Jul;40(4):679-86.

PMID:
10480391
21.

The post-Loeffler-Frosch era: contribution of German virologists.

Rott R.

Arch Virol Suppl. 1999;15:43-61.

PMID:
10470269
22.

Determinants of pantropism of the F1-R mutant of Sendai virus: specific mutations involved are in the F and M genes.

Okada H, Seto JT, McQueen NL, Klenk HD, Rott R, Tashiro M.

Arch Virol. 1998;143(12):2343-52.

PMID:
9930191
23.

One hundred years of animal virology.

Rott R, Siddell S.

J Gen Virol. 1998 Nov;79 ( Pt 11):2871-4. No abstract available.

PMID:
9820165
24.

3'-Processed mRNA is preferentially translated in Chlamydomonas reinhardtii chloroplasts.

Rott R, Levy H, Drager RG, Stern DB, Schuster G.

Mol Cell Biol. 1998 Aug;18(8):4605-11.

25.
26.

[Influenza, a special form of zoonosis].

Rott R.

Berl Munch Tierarztl Wochenschr. 1997 Jul-Aug;110(7-8):241-6. Review. German.

PMID:
9324923
27.

Failure to detect Borna disease virus infection in peripheral blood leukocytes from humans with psychiatric disorders.

Richt JA, Alexander RC, Herzog S, Hooper DC, Kean R, Spitsin S, Bechter K, Schüttler R, Feldmann H, Heiske A, Fu ZF, Dietzschold B, Rott R, Koprowski H.

J Neurovirol. 1997 Apr;3(2):174-8.

PMID:
9111180
28.
29.

Involvement of the mutated M protein in altered budding polarity of a pantropic mutant, F1-R, of Sendai virus.

Tashiro M, McQueen NL, Seto JT, Klenk HD, Rott R.

J Virol. 1996 Sep;70(9):5990-7.

30.

Influenza viruses, cell enzymes, and pathogenicity.

Rott R, Klenk HD, Nagai Y, Tashiro M.

Am J Respir Crit Care Med. 1995 Oct;152(4 Pt 2):S16-9. Review.

PMID:
7551406
31.

Trypsin-resistant protease activation mutants of an influenza virus.

Orlich M, Linder D, Rott R.

J Gen Virol. 1995 Mar;76 ( Pt 3):625-33.

PMID:
7897352
32.

Induction of protection against Borna disease by inoculation with high-dose-attenuated Borna disease virus.

Oldach D, Zink MC, Pyper JM, Herzog S, Rott R, Narayan O, Clements JE.

Virology. 1995 Jan 10;206(1):426-34.

33.

Natural and experimental Borna disease in animals.

Rott R, Becht H.

Curr Top Microbiol Immunol. 1995;190:17-30. Review. No abstract available.

PMID:
7789148
34.

Pathogenicity of influenza A/Seal/Mass/1/80 virus mutants for mammalian species.

Scheiblauer H, Kendal AP, Rott R.

Arch Virol. 1995;140(2):341-8.

PMID:
7710359
36.
37.
38.

Borna disease virus-specific T cells protect against or cause immunopathological Borna disease.

Richt JA, Schmeel A, Frese K, Carbone KM, Narayan O, Rott R.

J Exp Med. 1994 May 1;179(5):1467-73.

39.

[Expanded nuclear magnetic resonance studies in Borna disease virus seropositive psychiatric patients and control probands].

Bechter K, Bauer M, Estler HC, Herzog S, Schüttler R, Rott R.

Nervenarzt. 1994 Mar;65(3):169-74. German.

PMID:
8177357
40.

Demonstration of Borna disease virus-specific RNA in secretions of naturally infected horses by the polymerase chain reaction.

Richt JA, Herzog S, Haberzettl K, Rott R.

Med Microbiol Immunol. 1993 Dec;182(6):293-304.

PMID:
8121330
41.
42.

Genomic organization of the structural proteins of borna disease virus revealed by a cDNA clone encoding the 38-kDa protein.

Pyper JM, Richt JA, Brown L, Rott R, Narayan O, Clements JE.

Virology. 1993 Jul;195(1):229-38.

PMID:
8317098
43.

Localization of a Band 3-related protein in the mitochondria-rich cells of amphibian skin epithelium.

Devuyst O, Rott R, Denef JF, Crabbé J, Katz U.

Biol Cell. 1993;78(3):217-21.

PMID:
8241962
44.

Pathogenesis of Borna disease.

Stitz L, Bilzer T, Richt JA, Rott R.

Arch Virol Suppl. 1993;7:135-51. Review.

PMID:
8219798
45.

Borna disease virus: nature of the etiologic agent and significance of infection in man.

Richt JA, Herzog S, Pyper J, Clements JE, Narayan O, Bechter K, Rott R.

Arch Virol Suppl. 1993;7:101-9. Review.

PMID:
8219796
46.

Tryptase Clara, an activating protease for Sendai virus in rat lungs, is involved in pneumopathogenicity.

Tashiro M, Yokogoshi Y, Tobita K, Seto JT, Rott R, Kido H.

J Virol. 1992 Dec;66(12):7211-6.

47.

The pathogenic determinant of influenza virus.

Rott R.

Vet Microbiol. 1992 Nov;33(1-4):303-10. Review. Erratum in: Vet Microbiol 1993 Apr;34(4):398.

PMID:
1481363
49.

Interactions between bacteria and influenza A virus in the development of influenza pneumonia.

Scheiblauer H, Reinacher M, Tashiro M, Rott R.

J Infect Dis. 1992 Oct;166(4):783-91.

PMID:
1527412
50.

Infection with Borna disease virus: molecular and immunobiological characterization of the agent.

Richt JA, VandeWoude S, Zink MC, Clements JE, Herzog S, Stitz L, Rott R, Narayan O.

Clin Infect Dis. 1992 Jun;14(6):1240-50. Review.

PMID:
1623080

Supplemental Content

Support Center